SCHEMBL4635371

SCHEMBL4635371

NC1C2CN(C(=O)c3ccc(NC(=O)Nc4ccc(F)cc4)cc3)CC12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.60
PTPN1 P18031 1/20 0.50
HTT P42858 2/20 0.48
LMNA P02545 1/20 0.48
KMT2A Q03164 5/20 0.48
MAPT P10636 3/20 0.48
MEN1 O00255 3/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
MAPK1 P28482 1/20 0.48
NAMPT P43490 1/20 0.46
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
TLR2 O60603 2/20 0.44
TLR1 Q15399 2/20 0.44
TAAR1 Q96RJ0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635124 0.91 PTPN1 (0.54) EPHX2PTPN1HTTLMNAKMT2A
SCHEMBL4635067 0.89 HSD11B1 (0.51) KMT2AMEN1NPC1RAB9ACA12
SCHEMBL4636528 0.82 TSHR (0.54) HTTKMT2AMEN1NAMPT
SCHEMBL4084382 0.81 KMT2A (0.58) KMT2AMAPTNPC1RAB9ACA12
SCHEMBL4635095 0.81 KMT2A (0.70) HTTLMNAKMT2AMAPTMEN1
SCHEMBL4635408 0.75 MITF (0.54) EPHX2PTPN1HTTLMNAKMT2A
SCHEMBL3946296 0.75 EPHX2 (1.00) EPHX2HTTLMNAMAPTNPC1
SCHEMBL3944127 0.75 EPHX2 (1.00) EPHX2PTPN1HTTKMT2AMAPT
SCHEMBL4635923 0.74 CRHBP (0.47) HTTLMNAKMT2AMEN1NPC1
SCHEMBL4895759 0.74 CA12 (0.52) HTTLMNAKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 EPHX2 1251/4885PTPN1 2138/4885HTT 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.